X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AER-901
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AER-901
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AER-901
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
AER-901 is a drug-device combination that is designed to deliver potentially reverse-remodeling therapy with imatinib mesylate deeply and efficiently throughout the diseased tissue of the lung via the FOX® nebulizer.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AER-901
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
Proceeds from the transaction will be applied toward advancing AER-901, Aerami’s proprietary inhaled, nebulized formulation of imatinib into a planned Phase 2/3 clinical trial in 2022.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AER-901
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: FoxWayne Enterprises
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 07, 2021
Details:
Aerami will undertake its own PAH clinical development program in the US and other territories for AER-901, drug device combination product pursuant to a worldwide license from Vectura Group plc to develop and commercialize imatinib for the treatment of PAH.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AER-901
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hangzhou Chance Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
